Theravance Biopharma, Inc. Interest Expense Nonoperating
Theravance Biopharma, Inc. (TBPH) reported Interest Expense Nonoperating of $2.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-11
- Theravance Biopharma, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $582.00K, a 9.49% decline year-over-year.
- Theravance Biopharma, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $573.00K, a 9.05% decline year-over-year.
- Theravance Biopharma, Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $663.00K, a 2.95% increase year-over-year.
- Theravance Biopharma, Inc. interest expense nonoperating for the quarter ending 2025-03-31 was $643.00K, a 2.23% increase year-over-year.
- Theravance Biopharma, Inc. interest expense nonoperating for fiscal 2025 was $2.46M, a 3.34% decline from fiscal 2024.
- Theravance Biopharma, Inc. interest expense nonoperating for fiscal 2024 was $2.55M, a 8.34% increase from fiscal 2023.
- Theravance Biopharma, Inc. interest expense nonoperating for fiscal 2023 was $2.35M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.16M derived: sum of 2 quarters · filed 2026-03-23 | $1.82M derived: sum of 3 quarters · filed 2026-08-11 | $2.46M 10-K · filed 2026-03-23 |
| 2025-09-30 | $573.00K 10-Q · filed 2025-11-12 | $1.24M derived: sum of 2 quarters · filed 2026-08-11 | $1.88M 10-Q · filed 2025-11-12 | $2.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $663.00K 10-Q · filed 2026-08-11 | $1.31M 10-Q · filed 2026-08-11 | $1.95M derived: sum of 3 quarters · filed 2026-08-11 | $2.58M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $643.00K 10-Q · filed 2026-05-07 | $1.29M derived: sum of 2 quarters · filed 2026-05-07 | $1.92M derived: sum of 3 quarters · filed 2026-05-07 | $2.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $643.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.27M derived: sum of 2 quarters · filed 2026-03-23 | $1.92M derived: sum of 3 quarters · filed 2026-03-23 | $2.55M 10-K · filed 2026-03-23 |
| 2024-09-30 | $630.00K 10-Q · filed 2025-11-12 | $1.27M derived: sum of 2 quarters · filed 2025-11-12 | $1.90M 10-Q · filed 2025-11-12 | $2.53M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $644.00K 10-Q · filed 2025-08-13 | $1.27M 10-Q · filed 2025-08-13 | $1.90M derived: sum of 3 quarters · filed 2025-08-13 | $2.50M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $629.00K 10-Q · filed 2025-05-12 | $1.25M derived: sum of 2 quarters · filed 2025-05-12 | $1.86M derived: sum of 3 quarters · filed 2025-05-12 | $2.43M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $1.23M derived: sum of 2 quarters · filed 2025-03-07 | $1.80M derived: sum of 3 quarters · filed 2025-03-07 | $2.35M 10-K · filed 2025-03-07 |
| 2023-09-30 | $609.00K 10-Q · filed 2024-11-14 | $1.18M derived: sum of 2 quarters · filed 2024-11-14 | $1.73M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $568.00K 10-Q · filed 2024-08-08 | $1.12M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |